1 Biotech's Earnings the Market Got Completely Wrong

In this segment from Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass look at the recent earnings report from biotech company Celgene (NASDAQ: CELG  ) , to sift out the vital numbers that investors need to know.

The guys note that while the top line for Celgene came in a little light, the company did beat on bottom line estimates. Despite phenomenal sales growth numbers for key drugs Revlimid, Abraxane, and Pomalyst, David also mentions that this may be an unfortunate case of the market's expecting even more from a star performer. David also discusses the company's deal with Nogra Pharma for the development and marketing of an experimental Crohn's disease drug, and looks ahead to one crucial court date for Revlimid that could be a huge blow to Celgene if the court decision doesn't go in the company's favor.

Warren Buffett just bought nearly 9 million shares of this company
Imagine a company that rents a very specific and valuable piece of machinery for $41,000 per hour. (That's almost as much as the average American makes in a year!) And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click here to discover more about this industry-leading stock, and join Buffett in his quest for a veritable landslide of profits!


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2942654, ~/Articles/ArticleHandler.aspx, 10/23/2014 4:05:06 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement